Label

How We Work

Grant

Back

Print

Janssen Vaccines & Prevention B.V.


October 2013
to perform pre-clinical and clinical safety and immunogenicity studies to determine if inactivated poliomyelitis vaccine (IPV) derived from PER.C6 produced virus has the biological properties that would justify commercial production
$31,738,122
137
Polio
Global Development
2333 CP Leiden, Zuid-Holland

Visit Our Blog